Skip to main content
Press Release

First Site in Japan to Install Stereotaxis Technology Completes 250 Procedures

Stereotaxis, Inc., a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that Takatsuki General Hospital, a leading acute care institution near Osaka, has completed 250 ablation procedures using the Company’s Niobe® ES remote magnetic navigation system. Takatsuki was the first hospital to order and install the Niobe system after the technology was released in Japan in 2013.

“After being introduced to the Niobe system, I made it a personal goal to be the first physician to bring the next generation of cardiac ablation therapy to the people of Japan,” said Kohei Yamashiro, MD, Heart Rhythm Center Director, Takatsuki General Hospital. “I am pleased and proud that we have completed 250 procedures using the Niobe system, safely and effectively, with even the most complex arrhythmias and those that have failed to respond to other ablation treatments.”      

Dr. Yamashiro shared the example of a patient who had suffered from atrial tachycardia for 10 years, which could not be corrected with repeated manual ablation approaches. “With the Niobe system, we were able to completely cure the patient in a single procedure,” he said. “This technology has given us the unique ability to navigate an ablation catheter inside the heart with extreme precision for more exact lesion creation, and with significantly reduced radiation exposure to our patients and staff.”

“Our heart rhythm management services have been greatly enhanced by the important benefits of remote magnetic navigation technology, which has been well received across the region. We are delighted to deliver such an exciting innovation,” continued Dr. Yamashiro.

Takatsuki General Hospital underwent a complete renovation in 2015 to support the latest medical advances, such as the Niobe system, and provide higher quality, more integrated patient services. The first procedures with the Niobe system were performed in July of that year.  

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.